Most Cost-Beneficial Treatment Strategy for Each Antiviral Drug
| Drug Prescribed | No Treatment % | Test Before Treatment % | Empiric Treatment % |
|---|---|---|---|
| Note: Based on probability that a high-risk patient has influenza: population probability where strategy is most cost-beneficial. | |||
| Amantadine | <5 | -- | ≥5 |
| Rimantadine | <11 | -- | ≥11 |
| Zanamivir | <19 | ≥19 but ≤28 | >28 |
| Oseltamivir | <22 | ≥22 but ≤36 | >36 |